News
ACXP
4.520
+5.12%
0.220
Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 seco...
PR Newswire · 6d ago
Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For CDI At 16th Biennial Congress Of Anaerobe Society of America
New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat New in vitro data show ibezapolstat is
Benzinga · 08/02 13:02
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a ...
PR Newswire · 08/02 13:00
Acurx, Pharmaceuticals announces $4.25M direct offering
Clinical-stage biopharmaceutical company, Acurx Pharmaceuticals (NASDAQ:<a href="https://seekingalpha.com/symbol/ACXP?utm_medium=referral&utm_source=webull.com" title="Acurx Pharmaceuticals, Inc." target="_blank"...
Seekingalpha · 07/25 12:52
Acurx Pharmaceuticals, Inc. Announces $4.225M Registered Direct Offering
Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today
Benzinga · 07/25 12:33
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreeme...
PR Newswire · 07/25 12:30
BRIEF-Acurx Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Mln
BRIEF-Acurx Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Mln
Reuters · 07/01 12:52
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
Acurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07
Acurx Pharmaceuticals press release (NASDAQ:ACXP): Q1 GAAP EPS of -$0.26 beats by $0.07. Cash balance of $1.08M  as of March31, 2022
Seekingalpha · 05/11 11:15
-- Earnings Flash (ACXP) ACURX PHARMACEUTICALS Posts Q1 Loss $-0.26
MT Newswires · 05/11 07:15
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 firs...
PR Newswire · 04/29 12:01
Acurx Pharmaceuticals (NASDAQ:ACXP) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 03/24 19:23
Acurx Pharmaceuticals GAAP EPS of -$1.49 beats by $0.20
Acurx Pharmaceuticals press release (NASDAQ:ACXP): FY GAAP EPS of -$1.49 beats by $0.20. Cash balance of $12.96M as of December 31, 2021
Seekingalpha · 03/17 11:30
BRIEF-Acurx Pharmaceuticals Reports Q4, Full Year 2021 Results And Provides Business Update
reuters.com · 03/17 11:08
Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company's President & CEO, David P. Lu...
PR Newswire · 03/16 12:01
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth qu...
PR Newswire · 03/07 13:01
Acurx Pharmaceuticals' Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study
Following a period of bearish conditions, investors are anxiously awaiting the next big rally. A return to normal levels would help revitalize investor portfolios and confidence following a difficult month for the
Benzinga · 02/17 12:38
Acurx Announces Publication Of Positive Phase 2a Clinical Trial Results Of Ibezapolstat For CDI In Clinical Infectious Diseases
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial
Benzinga · 02/07 13:03
Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases
Publication of study presents:
PR Newswire · 02/07 13:01
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday.
Benzinga · 01/24 10:57
More
Webull provides a variety of real-time ACXP stock news. You can receive the latest news about Acurx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACXP
Acurx Pharmaceuticals, Inc., formerly Acurx Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company. The Company is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The Company develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA) and Streptococcus, including antibiotic resistant strains.